Chardan shalshes Omega shares target amid cash burn concerns

On Monday, Chardan Capital Markets revised its price target for Omega Therapeutics (NASDAQ:OMGA)shares , reducing it to $7.00 from the previous $12.00, while maintaining a Buy rating on the stock. The adjustment follows Omega's report on its fourth-quarter and full-year 2023 financial results, along with a corporate update.

Omega Therapeutics ended the year with $73.4 million in cash, equivalents, and marketable securities, a decrease from the $125 million reported at the end of 2022. To address this, Omega has executed a strategic reorganization, which includes a 35% reduction in workforce aimed at decreasing operating expenses.

Management now anticipates that the company's cash reserves, bolstered by a $5.1 million upfront payment from Novo Nordisk (NYSE:NVO), will be sufficient to support operations into the first quarter of 2025.

The company's cash burn from operations in the fourth quarter of 2023 was $17.1 million. Chardan projects a cash burn from operations totaling $62 million for the entirety of 2024. Omega's preclinical programs are now concentrated on three main areas: OTX-2101 for non-small cell lung cancer, the HNF4A program for liver regeneration, and a collaboration with Novo Nordisk to develop an epigenomic controller for obesity.

The reduction in the price target to $7.00 reflects changes in Chardan's financial model. These changes take into account the delayed timing of initial product revenue due to the updated product pipeline and the anticipated increased share count dilution, which is likely to arise from future fundraising efforts to finance clinical product development. Despite these challenges, Chardan continues to support Omega with a Buy rating.

Omega Therapeutics (NASDAQ:OMGA) has been navigating a challenging financial landscape, as evidenced by the latest metrics from InvestingPro. The company's market capitalization currently stands at a modest $201.32 million, and its revenue for the last twelve months as of Q4 2023 reached $3.09 million, registering a significant growth of 49.25%. Nevertheless, Omega's gross profit margin reveals a concerning figure of -2028.93%, underscoring the company's struggle with profitability.

InvestingPro Tips highlight that Omega is quickly burning through cash and has not been profitable over the last twelve months. This aligns with the company's reported cash burn from operations. Moreover, the stock is known for high price volatility, which can be seen in the price total returns, showing a drop of -15.12% over the last month but an impressive uptick of 69.77% over the last six months. Analysts at InvestingPro, who have access to additional tips, do not anticipate Omega to be profitable this year, which is a critical consideration for investors. For those seeking more comprehensive analysis, there are additional InvestingPro Tips available at: https://www.investing.com/pro/OMGA.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

For readers interested in a deeper dive into Omega Therapeutics' financials and prospects, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro, where you can find a total of 12 InvestingPro Tips to guide your investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.